Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR3217)
Drug Name
Oprozomib
Synonyms .
Indication Hodgkin lymphoma [ICD11: 2B30] Phase 2 [1]
Acute lymphoblastic leukemia [ICD11: ICD11: 2B33] Phase 1/2 [2]
Multiple myeloma [ICD11: ICD11: 2A83] Phase 1 [3]
Solid tumour/cancer [ICD11: ICD11: 2A00-2F9Z] Preclinical [4]
Structure
3D MOL is unavailable 2D MOL
Pharmaceutical Properties Molecular Weight 532.6 Topological Polar Surface Area 177
Heavy Atom Count 37 Rotatable Bond Count 14
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 9
Cross-matching ID
PubChem CID
25067547
CAS Number
935888-69-0
TTD Drug ID
D02BLD
Formula
C25H32N4O7S
Canonical SMILES
CC1=NC=C(S1)C(=O)N[C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@]3(CO3)C
InChI
InChI=1S/C25H32N4O7S/c1-15-26-11-20(37-15)24(33)29-19(13-35-4)23(32)28-18(12-34-3)22(31)27-17(21(30)25(2)14-36-25)10-16-8-6-5-7-9-16/h5-9,11,17-19H,10,12-14H2,1-4H3,(H,27,31)(H,28,32)(H,29,33)/t17-,18-,19-,25+/m0/s1
InChIKey
SWZXEVABPLUDIO-WSZYKNRRSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Oprozomib Metabolite M4 DM018429 N. A. Unclear - Unclear 1 [5]
Oprozomib Metabolite M5 DM016826
156596486
Unclear - Unclear 1 [5]
Oprozomib Metabolite M6 DM016843
156613742
Unclear - Unclear 1 [5]
Oprozomib Metabolite M7 DM016835
156596815
Unclear - Unclear 1 [5]
Oprozomib Metabolite M8 DM018430 N. A. Unclear - Unclear 1 [5]
Oprozomib Metabolite M9 DM018431 N. A. Unclear - Unclear 1 [5]
PR-025 DM016213
59217753
Unclear - Unclear 1 [5]
PR-176 DM016384
86715357
Unclear - Unclear 1 [5]
Oprozomib Metabolite M3 DM016840
156613648
Unclear - Unclear 2 [5]
Oprozomib Metabolite M3 DM016840
156613648
Other reaction - Cleavage 2 [5]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR010448 Oprozomib PR-176 Unclear - Unclear EPHX1 [5]
MR010450 Oprozomib PR-025 Unclear - Unclear PPD [5]
MR010452 Oprozomib Oprozomib Metabolite M4 Unclear - Unclear GST [5]
MR010453 Oprozomib Oprozomib Metabolite M5 Unclear - Unclear PPD [5]
MR010454 Oprozomib Oprozomib Metabolite M6 Unclear - Unclear CYP3A4 [5]
MR010455 Oprozomib Oprozomib Metabolite M7 Unclear - Unclear CYP3A4 [5]
MR010456 Oprozomib Oprozomib Metabolite M8 Unclear - Unclear CYP3A4 [5]
MR010457 Oprozomib Oprozomib Metabolite M9 Unclear - Unclear CYP3A4 [5]
MR010451 PR-025 Oprozomib Metabolite M3 Unclear - Unclear EPHX1 [5]
MR010449 PR-176 Oprozomib Metabolite M3 Other reaction - Cleavage PPD [5]
⏷ Show the Full List of 10 MR(s)
References
1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01832727) Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027317)
5 In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.